SCIENCE IS BROKEN: Shocking study reveals doctors reach “consensus” on anti-seizure medications despite a complete lack of evidence to support their decisions

Monday, July 31, 2017
By Paul Martin

by: Ethan Huff
NaturalNews.com
Monday, July 31, 2017

When parents take their children to the family doctor, they expect to receive treatments that align with the latest in sound science. But a new study has revealed that most doctors in North America rely on consensus rather than proof, at least when it comes to prescribing anti-seizure medications.

Published in the June 27 issue of Pediatric Neurology, the paper highlights how, despite the fact that there are dozens of anti-seizure medications from which to choose, most physicians choose from just a few of them. They do this not because these specific drugs necessarily work better, but because that’s what all the other doctors are prescribing.

Dr. William G. Gaillard, M.D., the division chief of Child Neurology and Epilepsy, Neurophysiology, and Critical Care Neurology at Children’s National Health System, says that part of the problem involves U.S. Food and Drug Administration (FDA) drug approvals for adults that don’t provide any information about how these drugs affect children.

But that’s just it: it’s precisely because so little research has been done with regards to anti-seizure medications in children that one would expect doctors to experiment from among the more than 20 different options they have at their disposal. Instead, they stick to just a few, even when these don’t actually work (and in some cases are extremely dangerous).

“With so many medications and so little data, one might think doctors would choose a wider variety of medicines when they prescribe to children with epilepsy,” Dr. Gaillard says.

Data suggests pill-pushing doctors don’t even think about what they’re prescribing to patients

The Rest…

Comments are closed.

Join the revolution in 2018. Revolution Radio is 100% volunteer ran. Any contributions are greatly appreciated. God bless!

Follow us on Twitter